This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

For patients requiring treatment of infections due to resistant, aerobic Gram-negative bacteria

​​​​​​​ZAVICEFTA® for the treatment of patients with suspected or documented Enterobacteriaceae and P. aeruginosa infection with resistance to ESBLs, KPC & OXA-48 carbapenemases and AmpC enzymes1–4

Ceftazidime

A broad spectrum, third-generation antipseudomonal cephalosporin with a well characterized efficacy and tolerability profile1,2.

Avibactam

A novel β-lactamase inhibitor, which allows ceftazidime to maintain activity in presence of certain resistance mechanisms1,2.

The combination of ceftazidime and avibactam provides broad spectrum Gram-negative pathogen coverage

Watch animation on Zavicefta mechanism of action

Header

This text is for block level content.P tags can go in here too

Gram-negative pathogen coverage by indication5-9*

Content

cIAIs

cUTIs

HAP/VAP

Citrobacter freundii

Enterobacter cloacae

Escherichia coli

Klebsiella oxytoca

Klebsiella pneumoniae

Proteus mirabilis

Pseudomonas aeruginosa

Serratia marcescens

*In vitro data indicate that the following species are not susceptible to ZAVICEFTA: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), anaerobes, Enterococcus spp., Stenotrophomonas maltophilia and Acinetobacter spp.

Explore more

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes10

Read more about patient risk factors in HAP/VAP,cUTI and cIAI


Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; CrCl, creatinine clearance; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing;

Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion 

Meronem® (meropenem triydrate) IV 1g 
​​​​​​​

​​​​​​​Meronem® (meropenem triydrate) IV 500mg 

Tazocin® (piperacillin sodium, tazobactam sodium) 2g/0.25g Powder for Solution for Infusion

Tazocin® (piperacillin sodium, tazobactam sodium) 4g/0.5g Powder for Solution for Infusion

Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics

Ciprofloxacin (ciprofloxacin lactate) 2 mg/ml Solution for Infusion 
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 bag £200.00
Click here for the Summary of Product Characteristics

Amikacin (amikacin sulfate) 500mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial pack £60.00
Click here for the Summary of Product Characteristics

Tobramycin (tobramycin)
Tobramycin 240mg/6ml solution for injection
Legal Category: Prescription Only Medicine (POM)
Basic NHS Cost: 1 vial £19.20
​​​​​​​Click here for the Summary of Product Characteristics

Tobramycin 80mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
Basic NHS Cost: 5 vial £20.80
​​​​​​​Click here for the Summary of Product Characteristics

References
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76
  5. Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65
  6. Miller BM, et al. Am J Infect Control 2016;44:134–7
  7. De Waele J, et al. Intensive Care Med 2018;44:189–96
  8. Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23
  9. Harris AD, et al. Emerg Infect Dis 2007;13:1144–9
  10. Bonine NG, et al. Am J Med Sci 2019;357:102–10
PP-ZVA-GBR-0839. June 2021

Access case studies and videos

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Alex Soriano

Infectious Disease Physician at Hospital Clinic in Barcelona, Spain, summarises key ZAVICEFTA data against other β-lactam/β-lactamase inhibitor combinations. He discusses ZAVICEFTA’s in vitro activity and broad-spectrum coverage against MDR P. aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae, Escherichia coli and ESBL-producing strains).

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No